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Open access under CC BY-NC-ND license.Serine and glycine are biosynthetically linked, and to-
gether provide the essential precursors for the synthesis
of proteins, nucleic acids, and lipids that are crucial to
cancer cell growth. Moreover, serine/glycine biosynthe-
sis also affects cellular antioxidative capacity, thus sup-
porting tumour homeostasis. A crucial contribution of
serine/glycine to cellular metabolism is through the
glycine cleavage system, which refuels one-carbon me-
tabolism; a complex cyclic metabolic network based on
chemical reactions of folate compounds. The importance
of serine/glycine metabolism is further highlighted by
genetic and functional evidence indicating that hyper-
activation of the serine/glycine biosynthetic pathway
drives oncogenesis. Recent developments in our under-
standing of these pathways provide novel translational
opportunities for drug development, dietary interven-
tion, and biomarker identification of human cancers.
Serine is a central hub of cancer metabolism
Cancer cells undergo specific metabolic reprogramming to
sustain cell growth and proliferation [1,2]. In addition to a
large energy requirement, cancer cells also accumulate
building blocks for the construction of new cellular compo-
nents, including nucleic acids, proteins, and lipids, as well
as important cofactors for the maintenance of cellular
redox status [3]. Glucose and glutamine are the main
sources used to maintain active essential metabolic path-
ways, such as glycolysis and anaplerotic flux of the tricar-
boxylic acid (TCA) cycle. In anabolic pathways, the serine
biosynthetic pathway represents a crucial turning point in
glucose conversion [4]. Imported serine and serine derived
from a branch of glycolysis can be converted to glycine,
which in turn provides carbon units for one-carbon metab-
olism. The synthesis of proteins, lipids, nucleic acids, and
other cofactors requires one-carbon metabolism, which is a0968-0004     
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reactions of folate compounds. The one-carbon unit pro-
ceeds in a cyclical pathway from which it is transferred to
other metabolic pathways. The importance of this meta-
bolic pathway is underlined by the fact that antifolate
chemotherapy is currently widely used in cancer treatment
and has been since its discovery more than 50 years ago [5].
In this review, we outline the recent advances in the
understanding and implications of serine and glycine me-
tabolism in cancer biology. Genetic and functional evidence
suggests that aberrant activation of the serine biosynthetic
pathway is an essential process in cancer pathogenesis.
Serine and glycine provide precursors for proteins, nucleic
acids, and lipids. In addition, regulation of serine biosyn-
thesis directly modulates cellular antioxidant capacity,
thus implying a function in the maintenance of tumour
homeostasis. All these findings may provide a new trans-
lational opportunity for drug development, dietary inter-
vention, and biomarker identification in order to provide
targeted antimetabolic therapy.
De novo serine biosynthesis
Glycolysis provides ATP and energy in most cell types, but
cancer cells extensively use glycolysis to sustain anabolism,
which is necessary for tumour growth. Serine biosynthesis is
a component of these glycolysis-diverting pathways. The
glycolytic intermediate 3-phosphoglycerate is converted
to serine following a three-step enzymatic reaction
(Figure 1). Cancer cells use phosphoglycerate dehydroge-
nase (PHGDH) and NAD to oxidise 10% of the 3-phospho-
glycerate generated from glycolysis into the serine precursor
3-phosphohydroxypyruvate [6]. Subsequent enzymes in the
pathway convert 3-phosphohydroxypyruvate into serine via
transamination (PSAT1) and phosphate ester hydrolysis
(PSPH) reactions. PHGDH expression is normally upregu-
lated in triple-negative breast cancer and in melanoma [7].
In these tumours, the genomic locus on human chromosome
1p12 that encodes PHGDH is subject to frequent amplifica-
tion, even though no oncogenes are included in this region
[8]. These analyses suggest that tumours containing
amplification of PHGDH might exploit serine biosynthesis
activity. In support of this, suppression of PHGDH in cell
lines with elevated PHGDH expression, but not in those
without, causes a strong decrease in cell proliferation and aTrends in Biochemical Sciences, April 2014, Vol. 39, No. 4 191
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Figure 1. De novo serine biosynthesis diverges from glycolysis. The serine synthesis pathway utilises the glycolytic intermediate 3P-glycerate, which is converted by
PHGDH, PSAT-1, and PSPH into serine. Removal of exogenous serine causes activation of its biosynthetic pathway. Serine accumulation accelerates glycolytic flux,
although allosteric activation of PKM2 by serine. p53, via TIGAR, and TAp73, via G6PD, facilitate activation of the PPP, promoting NADPH and nucleotide synthesis. p53-
dependent activation of p21 induces transient cell cycle arrest, blocking flux to purines, thus maintaining GSH synthesis. TAp73 drives glutamine/glutamate conversion by
inducing expression of GLS-2, thus pushing serine biosynthetic pathway, while it represses intracellular ROS controlling COX4i1 subunit expression. Abbreviations: 3P
glycerate, glycerate-3-phosphate; PHGDH, phosphoglycerate dehydrogenase; PKM2, pyruvate kinase M2; PPP, pentose phosphate pathway; ROS, reactive oxygen species;
COX4i1, cytochrome C oxidase subunit 4 isoform 1; G6PD, glucose-6-phosphate dehydrogenase; GLS-2, glutaminase-2; GSH, glutathione; PSAT-1, phosphoserine
aminotransferase 1; PSPH, phosphoserine phosphatase; TIGAR, TP53-inducible glycolysis and apoptosis regulator.
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expression of PHDGH in the breast epithelial cell line
MCF10A disrupts the acinar morphology and induces fur-
ther phenotypic alterations that predispose to malignant
transformation [9,10]. Therefore, PHDGH upregulation and
serine biosynthesis can be necessary and/or sufficient to
sustain cancer growth and oncogenic transformation.
Serine is a central metabolite for biosynthetic reactions,
but PHGDH suppression inhibits proliferation, even in cells
cultured in media containing exogenous serine. This sug-
gests that, besides the control of the intracellular serine
level, additional outputs and outcomes of serine biosynthet-
ic activity push the requirement of PHGDH upregulation in
cancer [7]. For instance, PSAT1 uses the PHGDH product 3-
phosphohydroxypyruvate to convert glutamate to a-keto-
glutarate. a-Ketoglutarate is an anaplerotic intermediate
that refuels the TCA cycle and sustains cancer metabolism.
A metabolic flux experiment with 13C-glutamine revealed
that the conversion of glutamine to glutamate and then a-
ketoglutarate, and other TCA intermediates, was signifi-
cantly reduced in cells in which PHGDH or PSAT-1 was192suppressed. Through these pathways the serine synthesis
pathway is a major contributor of TCA intermediates; it is
responsible for approximately half of the anaplerotic flux to
the TCA cycle.
De novo synthesis of serine provides precursors for a
variety of biosynthetic pathways, and accordingly, a pivot-
al aspect of the serine de novo synthesis is the conversion of
serine to glycine by serine hydroxymethyltransferase
(SHMT). As indicated above, glycine is a major source of
methyl groups for the one-carbon pools required for the
biosynthesis of glutathione (GSH), protein, purines and
DNA/histone methylation. The details of the role of glycine
in cancer cell metabolism are discussed in depth later.
Serine and the p53 family
The tumour suppressor p53 is emerging as an important
regulator of cellular metabolism. p53 is a key player in the
cellular response to stress in the form of numerous chal-
lenges, including DNA damage, hypoxia, and oncogene acti-
vation [11]. The complexity and diversity of these cellular
processes indicate roles for p53 in normal and cancer cell
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suppressor [12]. The ability of p53 to respond to nutrient
deficiencies lies in the established function of p53 as a
mediator of the cellular stress response. p53 has been asso-
ciated with the capacity of cancer cells to deal with serine
starvation and oxidative stress, and indeed, p53 helps cancer
cells to overcome serine starvation, preserving the cellular
antioxidant capacity. Cells lacking p53 fail to respond to
serine starvation due to oxidative stress, which leads to
reduced viability and severely impaired proliferation. Dur-
ing serine starvation, activation of the p53–p21 axis leads to
cell cycle arrest, which promotes cell survival by efficiently
channelling depleted serine stores to glutathione synthesis
[13]. The idea that cancer cells reprogram their metabolism
to counteract reactive oxygen species (ROS) production fits
with the suggestion that aerobic glycolysis (the Warburg
effect) is adopted to avoid the generation of metabolic ROS
[14]. These events underscore the relevance of p53 in coordi-
nating metabolic reprogramming in response to metabolic
stress. Recently, the p53-family member p73 was reported
to play a role in serine biosynthesis. Metabolic profiling of a
human cancer cell line revealed that TAp73 activates serine
biosynthesis, resulting in increased intracellular levels of
serine, glycine, and GSH. TAp73 depletion abrogates cancer
cell proliferation during serine/glycine deprivation, support-
ing the role of p73 in promoting serine biosynthesis to
help cancer cells under metabolic stress [15]. Therefore,
p73 and p53 together appear to help cancer cells cope with
the oxidative stress associated with serine starvation. This
concept supports the importance of serine in cancer cell
metabolism, indicating that many cancer cells may show
sensitivity to serine depletion, in particular when p53 and/or
p73 activity is altered. However, some cancer cells may
circumvent serine dependence through other genetic altera-
tions, such as PHGDH upregulation, which increases serine
biosynthesis. Serine depletion (either by removal from the
diet or in vivo enzymatic depletion) may represent an inno-
vative therapeutic strategy that could create additional
possibilities for human cancer treatment. The p53 family
directly influences various glycolysis-related pathways, en-
abling cells to respond to metabolic stress. In particular both
p53, via TP53-inducible glycolysis and apoptosis regulator
(TIGAR) [16], and p73, via glucose-6-phosphate dehydroge-
nase (G6PD) [17], favour the pentose phosphate shunt and
nucleotide biosynthesis. In addition, p53 [18,19], p63 [20],
and p73 [21] activate the expression of glutaminase-2
(GLS-2), promoting glutaminolysis, which interferes with
serine biosynthesis (Figure 1). Interestingly, likewise, the
oncogenic transcription factor c-Myc represses miR-23a and
miR-23b, resulting in upregulation of GLS-1 and glutami-
nolysis [22]. This underlines how a sophisticated integration
of oncogene and tumour suppressor signalling might result
in alteration of serine/glycine metabolism in cancer cells.
The complexity of this scenario highlights the importance of
a better understanding of the metabolic functions of onco-
genes and tumour suppressors, in particular p53 family, to
design novel therapeutic approaches in cancer.
Serine and pyruvate kinase (PK)M2
Allosteric positive and negative feedback is widely used to
regulate metabolic pathways swiftly, and in this case, serinecan allosterically fine-tune the glycolytic rate in cancer cells.
PK catalyses the last step of the glycolytic pathway to convert
phosphoenolpyruvate (PEP) to pyruvate and produce one
molecule of ATP. The M2 isoform of PK (PKM2) is a splice
variant of the PKM gene, which is predominantly expressed
in proliferating tissue [23,24]. A clear picture of PKM2 func-
tion in cancer is still unresolved. Although several pieces of
evidence suggest that a switch from PKM1 to PKM2 expres-
sion occurs in tumour cells during cancer transformation, the
recent generation of PKM2/mice has revealed that PKM2
deletion accelerates tumour onset in a Brca1-loss-driven
model of breast cancer. In contrast with PKM1, the M2
isoform shows low enzymatic activity. Lower PEP/pyruvate
conversion favours accumulation of glycolytic intermediates,
refuelling diverging anabolic pathways such as the pentose
phosphate pathway (PPP) and serine biosynthesis. Allosteric
regulations of PKM2 drive the shift between an active tetra-
meric form and a less-active dimer [25]. The tetramer has a
high affinity for PEP, whereas the low affinity of the dimer
results in reduced activity at physiological concentrations of
PEP [26]. Serine acts as allosteric activator of PKM2 [27].
Serine can activate recombinant PKM2 with a half-maximal
activation concentration (AC50) within the physiological
range of intracellular serine concentrations (1.3 mM). Serine
binding to PKM2 affects its enzymatic activity, lowering the
Michaelis constant (Km) of PKM2 for PEP by 2.3-fold [28].
This regulation implies that when serine is abundant, PKM2
is fully activated, allowing the consumption of glucose
through aerobic glycolysis. Upon serine deprivation, PKM2
activity is reduced, and pyruvate is diverted to a fuel-efficient
mode in the mitochondria, and glycolysis metabolites are
diverted to serine biosynthetic pathways to sustain cell
proliferation. Through this mechanism, serine supports aer-
obic glycolysis and lactate production; events that are critical
for cancer cell growth and survival.
Serine fuels glycine biosynthesis
Maintenance of the biosynthetic potential of the cell and of
its redox and epigenetic status relies heavily on the shut-
tling of carbon units by folate derivatives in the one-carbon
metabolic network. The complexity of this network and its
multifaceted involvement in cell proliferation and cancer
biology is now becoming clearer. Central to the aforemen-
tioned series of interconnected metabolic pathways is the
conversion of serine to glycine that is catalysed by the
enzyme serine hydroxymethyltransferase. The reaction
catalysed by SHMT represents a major source of methyl
groups for the one-carbon pools that are required for de
novo nucleotide biosynthesis and DNA methylation.
SHMT occupies a critical position at the convergence of
two key pathways for chemotherapeutic intervention: ser-
ine/glycine metabolism and nucleotide biosynthesis.
Mammalian SHMTs are pyridoxal 50-phosphate (PLP)-
dependent enzymes [29] that catalyse the reversible trans-
fer of the serine Cb to tetrahydrofolate (tetrahydropteroyl-
glutamate, H4PteGlu or THF) or its polyglutamylated
derivatives, yielding glycine and 5,10-CH2-H4PteGlu
(N5,N10-MTHF). In the human genome, two SHMT genes
are found; SHMT1, encoding the cytoplasmic isozyme
(SHMT1), and SHMT2, encoding the mitochondrial one
(SHMT2) [30]. SHMT2 encodes a second transcript that193
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SHMT2a) localises in the cytoplasm with SHMT1 and
accounts for the unexpected viability of Shmt1/ mice
[31]. Both SHMT1 and SHMT2 are transcriptional targets
of c-Myc [32], and changes in their expression and/or activity
have been shown in several tumours [33,34]. Together with
c-Myc-dependent upregulation of GLS-1, this indicates that
c-Myc plays a direct role in serine/glycine metabolism. In a
recent study, the SHMT1 gene was found to be dispensable
for Myc-induced lymphomagenesis, but mouse genetic mod-
els strongly suggest that the adaptability of tumour cells to
alterations in critical metabolic pathways is cell-context
dependent. For instance, no major impact of SHMT1 loss
was observed on colon adenocarcinoma initiation and devel-
opment in ApcMin mouse models, whereas acceleration of
lymphomagenesis was detected in the l-Myc mice, indicat-
ing a B cell specific event. These data argue against SHMT1
as a target for chemotherapy, although a deeper analysis of
the relative role of the two isoforms is still awaited [35]. This
evidence is clearly relevant when selecting patients for drug
treatments (see below).
The SHMT2 isoform appears to be preferentially involved
in the synthesis of mitochondrial dTMP, whereas SHMT1
and, to a lesser extent, SHMT2a participate to the synthesis
of nuclear dTMP, undergoing nuclear import during S-
phase and supplying N5,N10-MTHF during the thymidylate
cycle along with thymidylate synthase (TS) and dihydrofo-
late reductase (DHFR) [31]. N5,N10-MTHF is also utilised in
the de novo biosynthesis of purines. Recently, SHMT2 was
also found to be associated with the deubiquitylating com-
plex BRISC (Brcc36-containing isopeptidase complex,
which is involved in the interferon response) and to be
required for substrate targeting by BRISC, thus suggesting
potential new roles for this protein in the cytosol [36].
Glycine can also be generated from threonine by threo-
nine dehydrogenase (TDH) and glycine C-acetyltransfer-
ase (GCAT) (Figure 2). In vitro threonine deprivationGlucose
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Figure 2. De novo synthesised or imported serine and glycine refuel one-carbon
metabolism. One-carbon metabolism comprises two interconnected metabolic
cycles: the folate cycle and the methionine cycle. Different de novo or imported
inputs (red boxes), including glycine derived from serine and vitamin B12, converge
in this bimodular metabolic pathway. The. complex process produces multiple
outputs (blue boxes), including substrates for methylation reactions, proteins, lipids,
nucleotides, and reducing power against reactive oxygen species (ROS).
194promotes cell death that is associated with a dramatic
reduction of histone methylation. Metabolic flux demon-
strates that threonine enters one-carbon metabolism
through glycine cleavage [37,38]. Intracellular glycine
can also come from many other sources, such as betaine,
choline, N-methylglycine and dimethyl-glycine following a
series of demethylation reactions. The alternative to de
novo synthesis of glycine is extracellular uptake. Direct
import from the extracellular environment is enabled by
amino acid transporters.
As mentioned above, the folate metabolites provided by
SHMT-mediated reactions are also important in maintain-
ing normal methylation patterns and DNA stability, and
perturbation of folate levels has been shown to contribute to
abnormal methylation patterns and DNA instability in
many tumours and in lung cancer patients [33,39]. However,
another important contribution of glycine to cell metabolism
is associated with its introduction into the glycine cleavage
system, which refuels one-carbon metabolism.
One-carbon metabolism
The so-called one-carbon metabolism cycles carbon units
from different amino acids, generating several different
outputs and integrating several cellular nutrient statuses
(Figure 2). A central aspect of one-carbon metabolism is the
transformation of folate in all its different states. The
coupling of the folate cycle to the methionine cycle consti-
tutes a bicyclic pathway that circulates carbon units and is
collectively referred to as one-carbon metabolism. Folate is
a B vitamin naturally found in many western foods, where-
as the synthetically produced form, defined folic acid, is
often included in dietary supplements. In cells, folate is
reduced by a series of enzymes, leading to the generation of
tetrahydrofolate (THF) (Figure 3). THF contributes to
many metabolic reactions that move carbon units from
one position to another, generating the folate cycle. The
folate cycle is charged by the conversion of serine in glycine
(SHMT activity) and by the glycine cleavage system; gly-
cine dehydrogenase (GLDC; also known as GCSP) pro-
duces ammonia, carbon dioxide, and a carbon unit for
the methylation of THF. The folate cycle is then coupled
to the methionine cycle, with methyl-THF (mTHF) donat-
ing a carbon to homocysteine, methylating and converting
it to methionine.
The output of one-carbon metabolism includes a myriad
of components essential to the synthesis of all macromo-
lecules, such as proteins, lipids, and nucleic acids, used in
cellular growth and proliferation [40]. DNA synthesis
requires nucleotides, a limiting metabolic aspect of cell
proliferation. Methylation of dUMP by thymidylate
synthase produces dTMP by creating a THF from mTHF.
Additionally, purines require a folate pool for their gener-
ation through the intermediate 10-formyltetrahydrofolate
(F-THF), which is derived from 5,10-methylene-THF. The
methionine cycle is required for the synthesis of phospha-
tidylcholine, which contributes 50% of lipid membrane
content [41]. Methionine itself is required for protein syn-
thesis, but the adenylation of methionine produces S-ade-
nosylmethionine (SAM). SAM functions as a methyl donor
for other metabolic pathways that require methyl moieties,
including histone, DNA and RNA methylation, lysine and
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Figure 3. The folate and the methionine cycles exist and can be modulated
independently. Imported folic acid can be converted into reduced to THF and enter
the folic cycle. THF is in turn converted to me-THF by SHMT. me-THF is then either
converted to F-THF or reduced to mTHF by MTHFR. Demethylation of mTHF
completes the folate cycle and begins the methionine cycle, converting hCysteine
to methionine. Methionine is used to generate SAM, which is demethylated to form
SAH. After deadenylation by SAHH, the cycle performs a full turn with the conversion
of SAH in homocysteine. Abbreviations: F-THF, 10-formyltetrahydrofolate; hCysteine,
homocysteine; me-THF, 5,10-methylene-THF; mTHF, 5-methyltetrahydrofolate;
MTHFR, methylenetetrahydrofolate reductase; SAH, S-adenosylhomocysteine;
SAHH, S-adenosyl homocysteine hydrolase; SAM, S-adenosylmethionine; SHMT,
serine hydroxymethyl transferase; THF, tetrahydrofolate; MAT, methionine
adenosyltransferase; Methyl-TR, methyl-transferase.
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and methylation reactions that generate the lipid head
group [45]. Glycine/one-carbon metabolism also plays an
important role in the cellular redox balance. The reduction
of THF by tetrahydrofolate reductase produces one mole-
cule of NADP+ for each turn of the folate cycle. Modulation
of the NADP+/NADPH ratio contributes to the mainte-
nance of redox status. Glutathione, a tripeptide comprising
cysteine, glycine, and glutamate, is also important for the
maintenance of the NADP+/NADPH ratio and is the major
contributor to redox balance. Given their contributions to
balancing the redox state, cancer cells gain advantages
from alterations in these metabolic pathways.
Glycine metabolism is associated with cancer cell
proliferation
The second product of the SHMT reaction (i.e., glycine) can
be directed to the biosynthesis of purines, where it provides
two carbon atoms and a nitrogen atom in the purine ring.Table 1. Antimetabolite drugs in cancer
Drug Target enzyme 
Methotrexate DHFR 
Pemetrexed DHFR, TS 
Gemcitabine Ribonucleotide reductase 
5-FU Thymidylate reductase 
Pralatrexate DHFR 
DMFO Ornithine decaroboxylase 
Azanucleotides DNA methyltransferases 
Anti-serine biosynthesis PHGDH PSAT, PSPH 
Anti-glycine biosynthesis SHMT1, SHMT2 Glycine is also an integral component of glutathione,
therefore, the main antioxidant molecule of the cell, this
amino acid is also required to maintain the cellular redox
balance. In the mitochondria, glycine also fuels heme bio-
synthesis and thus sustains oxidative phosphorylation [46].
It has been recently shown that glycine uptake and catabo-
lism is able to promote tumourigenesis and malignancy,
suggesting that glycine metabolism could in principle be a
target for therapeutic intervention [47]. By looking at var-
iations in the level of more than 200 metabolites in the NCI-
60 cell line, Jain and coworkers showed that both glycine
consumption and expression of enzymes in the mitochon-
drial glycine biosynthetic pathway (but not the correspond-
ing cytosolic enzymes) correlate with the rate of proliferation
of cancer cells. Their results indicate a key role for the
mitochondria in supporting rapid cancer cell proliferation.
A recent meta-analysis, based on mRNA profiles of 1454
metabolic enzymes across 1981 tumours spanning 19 cancer
types, further underscored the importance of mitochondrial
compartmentalisation of one-carbon metabolism for cancer
[48]. Antagonising glycine uptake and its mitochondrial
biosynthesis preferentially impaired rapidly proliferating
cells; in particular, silencing the mitochondrial SHMT2 gene
and deprivation of extracellular glycine slowed down prolif-
eration in HeLa cells and other fast-proliferating cancer
cells by prolonging the G1 phase of the cell cycle [47].
Furthermore, upregulation of serine/glycine metabolism
correlates with cell proliferation and poor prognosis in
several tumours. Additionally, mathematical modelling of
the serine/glycine conversion rate in a panel of 60 well-
characterised cell lines (NCI60 panel) shows that glycine
conversion increases the proliferation rate and contributes
significantly to the biosynthetic requirements of purines,
ATP, and NADPH in cancer cells [49].
These studies confirm that glycine deprivation (from the
diet or by enzymatic depletion) may be a new route for
human cancer chemotherapy; thus, targeting SHMT is a
high priority in designing innovative therapeutic strategies.
Translational implications of serine and glycine
metabolism
A current challenge in cancer biology is the identification
of novel tools that may enable the selection of subsets of
patients for therapeutic intervention with chemically se-
lective pharmaceutical compounds. A landmark of cancer
chemotherapy, and possibly still the most widely used
drugs in medical oncology, are antimetabolites (anti-
folates); drugs that quench the effect of metabolites
on cellular processes (Table 1). Among the antifolates,Status Cancer
Approved Multiple cancers
Approved Multiple cancers
Approved Pancreatic cancer
Approved Colorectal cancer
Approved Peripheral Tcell lymphoma
Clinical trial Neuroblastoma
Approved Leukaemia
Preclinical studies
Preclinical studies
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Box 1. Outstanding questions
 How are expression levels of serine/glycine biosynthetic enzymes
regulated under basal and stress conditions in cancer cells?
 How is serine/glycine biosynthesis coordinated with the muta-
tional landscape (oncogene signalling) in cancer cells?
 How do serine, glycine, and one-carbon metabolism integrate and
balance their contribution to the antioxidant response, anabolism,
anaplerosis, or epigenetic status to sustain a cancer cell?
 Do serine and glycine equally contribute to the same phenomen-
on or do they retain exclusive functions?
 Does serine/glycine biosynthesis pathway affect cancer onset or
only contribute to cancer progression?
 Would dietary intervention synergise with classic chemothera-
peutic protocols in cancer patient treatments?
Review Trends in Biochemical Sciences April 2014, Vol. 39, No. 4methotrexate and pemetrexed constitute a major class of
cancer chemotherapy agents and are currently used as
frontline chemotherapy for a diverse range of cancers,
including acute lymphoblastic leukaemia, breast cancer,
bladder cancer, and lymphomas. Methotrexate and peme-
trexed have the ability to bind and inhibit human SHMT in
vitro [50]. The action of mitochondrial enzymes in the
metabolism of serine and glycine, in addition to those
involved in folate metabolism, have been recently shown
to be determinants of the response to methotrexate, sug-
gesting that patients whose tumours show upregulation
of serine and glycine mitochondrial enzymes are sensitive
to folate antagonists targeting thymidylate or purine
biosynthesis [51]. Antifolates show selectivity for rapidly
proliferating tumours in patients with overexpression
of genes coding for mitochondrial folate metabolism
enzymes. About 25% of patients with cancers manifesting
this phenotype could be selected for treatment with
thymidylate and purine biosynthesis inhibitors. The iden-
tification of novel strategies, including those specifically
targeting SHMT, allow the emergence of new antimeta-
bolites and enlarge the therapeutic window (and efficacy)
of current approaches. To design a successful clinical
strategy, however, it will be important to select patients
and find the right combinations of inhibitors targeting
several metabolic enzymes in the serine/glycine pathway.
Alternative approaches aim to target downstream path-
ways of serine/glycine/one-carbon metabolism. Potent and
clinically approved inhibitors of thymidylate and purine
biosynthesis include pralatrexate and 5-fluorouracil (5-
FU); methotrexate and pemetrexed, which are wide-selec-
tivity antifolate molecules, also show antagonistic capacity
[52]. 5-FU is a standard agent for the treatment of several
cancer types. Mimicking uracil, 5-FU inhibits thymidylate
synthase, resulting in impairment of the methylation of
dUMP to dTMP and folate cycle disruption [53]. 5-FU is
also intercellularly converted to 5-fluorouridine (5-FUDR),
which incorporates into rRNA molecules and leads to inhi-
bition of rRNA processing. As a result, 5-FUDR induces a
p53-dependent cell cycle arrest and/or apoptosis [54].
However other approaches targeting mechanisms
downstream of serine/glycine/one-carbon metabolism aim
to modulate the epigenetic status of tumours. Inhibitors of
methyltransferases, which affect post-translational mod-
ifications of histones and DNA, belong to this group. Sev-
eral of these compounds are currently under preclinical
evaluation or in early-stage clinical trials [55,56]. Preclini-
cal studies are also ongoing for small molecules targeting
the catalytic site of metabolic enzymes such as PHGDH
PSAT, PSPH, and GLDC [6]. A different and novel ap-
proach to target cancer metabolism is the design of a
complementary diet or nutrient modification to add to
pharmacological agents. Supporting this idea, low glucose
intake can have negative effects on tumour growth and
progression [57,58]. Consistent with that effect, high car-
bohydrate intake is positively correlated with cancer inci-
dence [59,60]. In addition, an in vivo study in mice explored
the possibility of restricting serine and glycine metabolism
for cancer intervention. In the absence of p53, serine and
glycine withdrawal had an even greater effect, suggesting
an epistatic interaction between p53 and the availability of196serine and glycine [13]. However, the complexity of the
relation between diet and one-carbon metabolism is
highlighted by the observation that reduced administra-
tion of folate is also associated with breast and colorectal
cancer [61].
Concluding remarks
A surge of interest in the study of cancer metabolism has
occurred in the past few years, resulting in the constant
expansion of the compendium of metabolic pathways es-
sential to cancer biology. The recent advances in under-
standing the relation between cancer and metabolism have
highlighted the relevance of serine/glycine biosynthesis
and one-carbon metabolism. Genetic and functional evi-
dence support the importance of the activity of these path-
ways as drivers of oncogenesis. Genetic activation of serine
biosynthesis has been proven to drive directly cancer pro-
liferation and predispose normal mammary epithelial cell
line to cancer transformation; but how are these metabolic
pathways integrated into the mutational landscape of a
cancer cell? Little is known in this regard, or of the molec-
ular mechanisms that govern the outcome of serine/glycine
biosynthesis and one-carbon metabolism. A biochemical
dissection of how these metabolic routes contribute to
cancer biology is mandatory to explore its therapeutic
potential. How do the inputs and the outputs integrate
and balance their contribution to antioxidant response,
anabolism, anaplerosis or epigenetic status? The knowl-
edge currently available underlines the relevance of serine
biosynthesis to preserve the antioxidant response of cancer
cells. That p53/ tumours cannot mount an antioxidant
response in serine/glycine starvation highlights the impor-
tance of these metabolites, particularly their integration in
the molecular context for the redox homeostasis of cancer
cells. In light of their importance for the antioxidant
response, it would also be interesting to investigate the
contribution of serine/glycine biosynthesis to the early
stage of tumourigenesis. Do these pathways affect cancer
onset or only contribute to cancer progression and metas-
tasis? Elucidation of these aspects, and others, might
provide alternative clinical strategies, potentially enabling
the design of personalised therapy for cancer patients
(Box 1, outstanding questions). Mathematical models, in-
tegrative bioinformatics approaches, and metabolomics
should speed development of the field. Building a concep-
tual framework to understand metabolic regulation in
cancer is a challenging but compulsory endeavour that
Review Trends in Biochemical Sciences April 2014, Vol. 39, No. 4is still in its infancy. To design novel therapeutic
approaches with high selectivity and efficacy, we need to
understand not only the differences between normal and
tumour cells, but also why some cancer cells are more
dependent on specific metabolic pathways than others.
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